CAMBRIDGE, Mass.--(BUSINESS WIRE)--Permeon™ Biologics, a biopharmaceutical company pioneering a novel class of intracellular protein biologics, today announced the appointment of Katherine S. Bowdish, Ph.D., as president and chief scientific officer. Dr. Bowdish also joins the Permeon board of directors. Previously, Dr. Bowdish was the co-founder, president and chief executive officer of Anaphore, a platform-based drug development company pioneering Atrimers™, a new class of trivalent protein pharmaceuticals. Before founding Anaphore, she founded Prolifaron, a leading innovator of antibody technologies that grew through large pharma partnerships and ultimately merged with Alexion Pharmaceuticals. Following that merger, Dr. Bowdish served as president of Alexion Antibody Technologies, Inc. and senior vice president antibody discovery of Alexion Pharmaceuticals.
